Khandaker Partners, Inc., a New York Research Firm, Updates Market Report of Pure H20 Bio-Technologies, Inc.

BOCA RATON, Fla. -- Pure H20 Bio-Technologies, Inc. (Pink Sheets:PHBT) today announced that Khandaker Partners, Inc., a N.Y. Research Firm, updated a market report on PHBT. The following Khandaker Market Report is for marketing purposes and consumer awareness. Its content is based on an overview report by Khandaker's Medical Doctors who are senior analysts, leaving a transparent unbiased company highlight and overview based on merit. Khandaker Partners' previous coverage of PHBT can be viewed on the company's website: http://www.pureh20biotech.com

About PHBT

PHBT is a publicly-held company specializing in the manufacture, design and sale of its unique residential, commercial and hospital systems that combat waterborne disease.

Following is the updated market report by Khandaker Partners:

Khandaker Partners

PHBT: MARKET ALERT

Pure H20 Bio-Technologies, Inc (Pink Sheets OTC-BB) Symbol PHBT. Industry: BioTechnology

Investment Highlights:

- Patent pending on Iodine Water Treatment System and Method

- 10% annual growth rate for residential water filtration market

- Industrial water filtration market valued at $35 billion and growing 8% annually

- Receipt of a Letter of Intent from the Export-Import Bank of the United States, Washington D.C. for financial support up to $1.5 million for its St. John's Antigua Project.

- Projected revenue Year 1 - $6m, Year 2 - $14m, Year 3 - $21m, Year 4 - $34m, Year 5 - $57m

- Experienced management team merges extensive business experience with vast range of scientific knowledge

- Pure H20 received a letter of intent for up to $1.5 million in financing from the Export-Import Bank of the United States, Washington, D.C. to support its intended St. John's, Antigua Project. Pure H20 intends to ship its equipment and products to Antigua, to help relieve the country's perpetual shortage of potable water.

- Pure H20's water disinfection systems are based on a unique iodine disinfection and filtration methodology. The development of the product processes and related testing is completed. Using an exclusive leading edge iodine storage and dispensing process, in conjunction with granular activated carbon filtration.

- Pure H20 confirmed laboratory tests by Clancy Environmental Consultants (CEC), a nationally recognized microbiological/water expert, located in St. Albans, Vermont, efficacy of iodine at low concentrations reduced the number of microbes by approximately 6 logs (99.9999% killed) within 5 minutes and 8 logs (99.999999% killed) within ten minutes. These included Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa.) CEC has served the United States Environomental Protection Agency (EPA), American Waterworks Association (AWA) and private industry in an advisory and consultant capacity.

- Trading Data
      Stock Price: $0.012
      Shs. Outstanding: 49,407,060
      Volume: 2,147,304
      Beta: 0.57

Overview: Pure H20 Bio-Technologies, Inc. ("Pure H20" or "the Company") a Florida corporation, designs, develops, manufactures and markets potable water disinfection systems, particularly medical point-of-use, under-the-counter, whole house and well systems primarily used for commercial and residential applications. Pure H20's unique high-integrity systems address lead, organic, and other contamination such as waterborne disease agents, heavy metals and objectionable biomass. Products can be viewed on the PHBT's website: http://www.pureh20biotech.com . The Company utilizes the technological advances in micro-biotechnology to improve the safety of drinking water. Pure H20 has systematically and successfully addressed lead and other chemical and toxicological contamination, as well as waterborne diseases. The Company's decision to utilize iodine in its chemical treatment of water is based upon known properties, including iodine's ability to kill or deactivate all known types of disease-causing, waterborne microorganisms, such as bacteria, viruses and protozoa cysts.

Market: Water Filtration Market: The industrial water filtration market is estimated at $35 billion, and growing 8% annually. The U.S. household water filtration market is $500 million and growing 10% annually. Existing technologies use carbon block filters, reducing microbial contamination, but can't account for the wide array of microorganism diameter depending on their lifecycle. Pure H20's multi-stage system, using absolute micron carbon pre and post filters with controlled release USP iodine, is designed to treat the bacterial pathogens often missed by the two well known home systems. At least 12% of US households treat their drinking water. By 2010, that number is expected to increase to 40%, demonstrating Pure H20's market potential as the demand for high purity water rises rapidly. The Company's strategy focuses on Pure H20 systems' unique ability to provide disinfection in drinking water. Each system component has a specific performance feature that leads to direct benefits for the end user. Pure H20 intends to utilize direct marketing approaches to effectively move the array of water disinfection and treatment products including: direct mail and cable television to enhance the sales efforts of distributors serving the residential market. The Company will utilize combinations of direct contacts along with consulting enginering groups to approach the commercial and resdiential market segments. These markets generally require a professionally designed drinking water system that fits a specific applications and criteria. Under-the-counter and Whole house systems will be marketed primarily through developers and home builders. Offering this product to developers and home builders provides home buyers with the option to an all-inclusive networked water disinfection system included in the purchase of the home. Pure H20 has developed and designed a point-of-use disinfection system primarily for hospital use. These systems provide the necessary added protection for cancer and other immune-compromised patients.

Legal Notes and Disclosures: This report has been prepared by Khandaker Partners div of ("KP") with the assistance of Pure H20 BioTechnologies Inc (the "Company") based upon information provided by the Company. KP has not independently verified such information. In addition, KP has been compensated by the Company in cash for its services. Some of the information in this report relates to future events or future business and financial performance. Such statements constitute forward-looking information with in the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in Pure H20 Bio-Technologies, Inc.'s reports on Forms 10-K, 10-Q, and 8-K. The content of this report with respect to Pure H2O BioTechnologies Inc. has been compiled primarily from information available to the public released by Pure H20 Bio-Technologies through news releases and SEC filings. Pure H20 Bio-Technologies is solely responsible for the accuracy of that information. Information as to other companies has been prepared from publicly available information and has not been independently verified by Pure H20 Bio-Technologies or KP. Certain summaries of scientific activities and outcomes have been condensed to aid the reader in gaining a general understanding. For more complete information about Pure H2O Bio-Technologies Inc, the reader is directed to the Company's website at http://www.pureh20Biotech.com. This report is published solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state. Past performance does not guarantee future performance. Free additional information about Pure H20 Bio-technologies Inc, and its public filings, as well as free copies of this report can be obtained in either a paper or electronic format by calling [phone].